Total Payments
$535,728
2024 Payments
$84,427
Companies
25
Transactions
546
Medicare Patients
388
Medicare Billing
$56,739
Payment Breakdown by Category
Consulting$396,662 (74.0%)
Travel$71,955 (13.4%)
Research$31,806 (5.9%)
Other$23,085 (4.3%)
Food & Beverage$12,138 (2.3%)
Education$82.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $396,662 | 148 | 74.0% |
| Travel and Lodging | $71,955 | 148 | 13.4% |
| Unspecified | $31,806 | 48 | 5.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,450 | 7 | 4.0% |
| Food and Beverage | $12,138 | 190 | 2.3% |
| Honoraria | $1,635 | 1 | 0.3% |
| Education | $82.02 | 4 | 0.0% |
Payments by Type
General
$503,922
498 transactions
Research
$31,806
48 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $104,026 | 118 | $0 (2024) |
| Merck Sharp & Dohme LLC | $74,585 | 117 | $0 (2024) |
| Novo Nordisk AS | $44,242 | 10 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $37,400 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $35,024 | 28 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $33,649 | 33 | $0 (2024) |
| GlaxoSmithKline, LLC. | $29,595 | 64 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $28,411 | 11 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $27,063 | 11 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $24,043 | 20 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $84,427 | 54 | Novo Nordisk AS ($20,347) |
| 2023 | $62,224 | 40 | Novo Nordisk AS ($23,895) |
| 2022 | $55,890 | 54 | BOSTON SCIENTIFIC CORPORATION ($15,983) |
| 2021 | $40,831 | 27 | BOSTON SCIENTIFIC CORPORATION ($12,744) |
| 2020 | $37,943 | 29 | Intercept Pharmaceuticals, Inc. ($11,000) |
| 2019 | $113,110 | 129 | Novartis Pharmaceuticals Corporation ($24,295) |
| 2018 | $53,710 | 102 | Bayer HealthCare Pharmaceuticals Inc. ($16,719) |
| 2017 | $87,591 | 111 | GlaxoSmithKline, LLC. ($24,809) |
All Payment Transactions
546 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $8,500.00 | General |
| 12/06/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $29.69 | General |
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.58 | General |
| 12/04/2024 | AstraZeneca AB | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,985.00 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,445.67 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 11/16/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $50.42 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $170.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Travel and Lodging | In-kind items and services | $254.52 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Travel and Lodging | In-kind items and services | $185.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 10/01/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $12,981.25 | General |
| 10/01/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $6,510.15 | General |
| 10/01/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $503.73 | General |
| 10/01/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $250.23 | General |
| 10/01/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $101.31 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,992.50 | General |
| 09/06/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Hepatology / Gastroenterology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A long term, randomised, double blind, placebo controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus | GlaxoSmithKline, LLC. | $24,215 | 15 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,819 | 11 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $1,446 | 1 |
| CLCZ696DUS01 | Novartis Pharma AG | $1,267 | 1 |
| Research Medical Writing and Publication Support | Novartis Pharmaceuticals Corporation | $1,117 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 25 | 60 | $10,440 | $3,637 |
| 2022 | 4 | 122 | 294 | $60,128 | $17,780 |
| 2021 | 4 | 129 | 323 | $63,816 | $18,892 |
| 2020 | 4 | 112 | 268 | $55,018 | $16,430 |
Total Patients
388
Total Services
945
Medicare Billing
$56,739
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 60 | $10,440 | $3,637 | 34.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 64 | 233 | $40,542 | $12,473 | 30.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $10,206 | $2,698 | 26.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 23 | 25 | $6,800 | $1,933 | 28.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 15 | $2,580 | $675.83 | 26.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 63 | 254 | $44,196 | $13,546 | 30.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $8,748 | $2,490 | 28.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 19 | 21 | $5,712 | $1,566 | 27.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 29 | 30 | $5,160 | $1,290 | 25.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 54 | 207 | $36,018 | $11,384 | 31.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 22 | $10,692 | $2,938 | 27.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 15 | 16 | $4,352 | $1,260 | 28.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 23 | $3,956 | $847.26 | 21.4% |
About Dr. Adrian Hernandez, M.D
Dr. Adrian Hernandez, M.D is a Cardiovascular Disease healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902980063.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adrian Hernandez, M.D has received a total of $535,728 in payments from pharmaceutical and medical device companies, with $84,427 received in 2024. These payments were reported across 546 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($396,662).
As a Medicare-enrolled provider, Hernandez has provided services to 388 Medicare beneficiaries, totaling 945 services with total Medicare billing of $56,739. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 03/22/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1902980063
Products in Payments
- JARDIANCE (Drug) $30,582
- OCALIVA (Drug) $26,400
- TANZEUM (Biological) $24,444
- FARXIGA (Drug) $23,446
- MK-1242 (Drug) $23,326
- CLINICAL TRIAL PRODUCT (Device) $22,807
- Non-Covered $19,719
- CAMZYOS (Drug) $15,150
- NO PRODUCT DISCUSSED (Drug) $14,426
- SOLIQUA 100/33 (Drug) $13,985
- General - Therapies (Device) $13,500
- ENTRESTO (Drug) $12,712
- GENERAL - THERAPIES (Device) $10,402
- GENERAL THERAPIES (Device) $8,106
- EMBLEM (Device) $8,080
- GENERAL EP (Device) $8,000
- LOKELMA (Drug) $6,584
- GENERAL THERAPIES (Device) $6,515
- LEQVIO (Drug) $4,821
- Ozempic (Drug) $4,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Durham
R. Williams, M.d, M.D
Cardiovascular Disease — Payments: $3.3M
Cardiovascular Disease $3.3M
Jonathan Piccini, M.d., M.h.s, M.D., M.H.S
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
David Kong, M.d., A.m., D.m.t, M.D., A.M., D.M.T
Cardiovascular Disease — Payments: $576,585
Cardiovascular Disease $576,585
Chris Granger, M.d, M.D
Cardiovascular Disease — Payments: $510,675
Cardiovascular Disease $510,675
Christopher Kontos, M.d, M.D
Cardiovascular Disease — Payments: $473,112
Cardiovascular Disease $473,112
Gary Felker, M.d, M.D
Cardiovascular Disease — Payments: $440,506
Cardiovascular Disease $440,506